Format

Send to

Choose Destination
Cancer J. 2014 Mar-Apr;20(2):156-9. doi: 10.1097/PPO.0000000000000029.

NKG2D CARs as cell therapy for cancer.

Author information

1
From the *Department of Microbiology and Immunology, and †Section of Hematology and Oncology, Department of Medicine, The Geisel School of Medicine at Dartmouth, Lebanon, NH.

Abstract

The NKG2D cell receptor and its ligands have attracted considerable interest as a potential strategy to attack tumor cells. NKG2D ligands are expressed on most types of tumors, and they demonstrate relative selectivity of ligand expression on tumor cells compared to healthy cells. Several different variants of NKG2D-based chimeric antigen receptors (CARs) have been developed, and extensive in vivo mechanistic studies performed demonstrated that cytotoxicity and cytokines are important for the efficacy NKG2D CAR adoptive T-cell therapy. NKG2D CARs target tumor cells, and they also target immunosuppressive cells within the tumor microenvironment. Under certain conditions, NKG2D ligand expression can be found on nontumor tissue, so potential off-tumor toxicity remains. In this article, we review the use of NKG2D as a basis for CAR targeting of tumors.

PMID:
24667963
PMCID:
PMC4017323
DOI:
10.1097/PPO.0000000000000029
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center